Involvement of the JNK activation in terbinafine-induced p21 up-regulation and DNA synthesis inhibition in human vascular endothelial cells

Journal of Cellular Biochemistry

Volumn 108, Issue 4, 2009, Pages 860-866

  Hsu, Sung Po ^a,b   Ho, Pei Yin ^c   Liang, Yu Chih ^c   Ho, Yuan Soon ^c   Lee, Wen Sen ^b,c  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

ERK; JNK; p21; p53; Terbinafine

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE KINASE 7; PROTEIN P21; PROTEIN P53; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; TERBINAFINE;

ARTICLE; CELL CYCLE ARREST; DNA SYNTHESIS INHIBITION; DRUG ACTIVITY; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME REPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING;

CELL PROLIFERATION; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA, COMPLEMENTARY; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 8; NAPHTHALENES; NEOVASCULARIZATION, PATHOLOGIC; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 70350446612     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22314     Document Type: Article

References (43)

1. Abdel-Rahman SM, Nahata MC. 1997. Oral terbinafine: A new antifungal agent. Annu Pharmacother 31:445-456.
2. Antlsperger DS, Dirsch VM, Ferreira D, Su JL, Kuo ML, Vollmar AM. 2003. Ajoene-induced cell death in human promyeloleukemic cells does not require JNK but is amplified by the inhibition of ERK. Oncogene 22:582-589. (Pubitemid 36188615)
3. Bellon G, Martiny L, Robinet A. 2004. Matrix metalloproteinases and matrikines in angiogenesis. Crit Rev Oncol Hematol 49:203-220.
4. Bussolino F, Mantovani A, Persico G. 1997. Molecular mechanisms of blood vessel formation. Trends Biochem Sci 22:251-256. (Pubitemid 27310945)
5. Carmeliet P. 2005. Angiogenesis in life, disease and medicine. Nature 438:932-936.
6. Chen CH, Wang WJ, Kuo JC, Tsai HC, Lin JR, Chang ZF, Chen RH. 2005. Bidirectional signals transduced by DAPK-ERK interaction promote the apoptotic effect of DAPK. EMBO J 24:294-304.
7. Davis RJ. 2000. Signal transduction by the JNK group of MAP kinases. Cell 103:239-252.
8. Dhanasekaran DN, Reddy EP. 2008. JNK signaling in apoptosis. Oncogene 27:6245-6251.
9. Du L, Lyle CS, Obey TB, Gaarde WA, Muir JA, Bennett BL, Chambers TC. 2004. Inhibition of cell proliferation and cell cycle progression by specific inhibition of basal JNK activity: Evidence that mitotic Bcl-2 phosphorylation is JNK-independent. J Biol Chem 279:11957-11966. (Pubitemid 38401701)
10. Fuchs SY, Adler V, Pincus MR, Ronai Z. 1998a. MEKK1/JNK signaling stabilizes and activates p53. Proc Natl Acad Sci USA 95:10541-10546. (Pubitemid 28413103)
11. Fuchs SY, Fried VA, Ronai Z. 1998b. Stress-activated kinases regulate protein stability. Oncogene 17:1483-1490. (Pubitemid 28458417)
12. Gallo KA, Johnson GL. 2002. Mixed-lineage kinase control of JNK and p38 MAPK pathways. Nat Rev Mol Cell Biol 3:663-672.
13. Garrington TP, Johnson GL. 1999. Organization and regulation of mitogen-activated protein kinase signaling pathways. Curr Opin Cell Biol 11:211-218. (Pubitemid 29164036)
14. Gupta MK, Qin RY. 2003. Mechanism and its regulation of tumor-induced angiogenesis. World J Gastroenterol 9:1144-1155.
15. Hagemann C, Blank JL. 2001. The ups and downs of MEK kinase interactions. Cell Signal 13:863-875. (Pubitemid 33139788)
16. Ho PY, Liang YC, Ho YS, Chen CT, Lee WS. 2004. Inhibition of human vascular endothelial cells proliferation by terbinafine. Int J Cancer 111:51-59. (Pubitemid 38859282)
17. Ho PY, Hsu SP, Liang YC, Kuo ML, Ho YS, Lee WS. 2008. Inhibition of the ERK phosphorylation plays a role in terbinafine-induced p21 up-regulation and DNA synthesis inhibition in human vascular endothelial cells. Toxicol Appl Pharmacol 229:86-93.
18. Hu YL, Li S, Shyy JY, Chien S. 1999. Sustained JNK activation induces endothelial apoptosis: Studies with colchicine and shear stress. Am J Physiol 277:H1593-H1599. (Pubitemid 29522693)
19. Huang HS, Liu ZM, Ding L, Chang WC, Hsu PY, Wang SH, Chi CC, Chuang CH. 2006. Opposite effect of ERK1/2 and JNK on p53-independent p21WAF1/CIP1 activation involved in the arsenic trioxide-induced human epidermoid carcinoma A431 cellular cytotoxicity. J Biomed Sci 13:113-125. (Pubitemid 43162510)
20. Jacobs-Helber SM, Sawyer ST. 2004. Jun N-terminal kinase promotes proliferation of immature erythroid cells and erythropoietin-dependent cell lines. Blood 104:696-703.
21. Johnson GL, Nakamura K. 2007. The c-jun kinase/stress-activated pathway: Regulation, function and role in human disease. Biochim Biophys Acta 1773:1341-1348. (Pubitemid 47125977)
22. Kapur R, Chandra S, Cooper R, McCarthy J, Williams DA. 2002. Role of p38 and ERK MAP kinase in proliferation of erythroid progenitors in response to stimulation by soluble and membrane isoforms of stem cell factor. Blood 100:1287-1293. (Pubitemid 34864283)
23. Kim SJ, Ju JW, Oh CD, Yoon YM, Song WK, Kim JH, Yoo YJ, Bang OS, Kang SS, Chun JS. 2002. ERK-1/2 and p38 kinase oppositely regulate nitric oxide-induced apoptosis of chondrocytes in association with p53, caspase-3, and differentiation status. J Biol Chem 277:1332-1339.
24. Kim HJ, Chakravarti N, Oridate N, Choe C, Claret FX, Lotan R. 2006. N-(4-hydroxyphenyl)retinamide-induced apoptosis triggered by reactive oxygen species is mediated by activation of MAPKs in head and neck squamous carcinoma cells. Oncogene 25:2785-2794.
25. Kwon YW, Kwon KS, Moon HE, Park JA, Choi KS, Kim YS, Jang HS, Oh CK, Lee YM, Kwon YG, Lee YS, Kim KW. 2004. Insulin-like growth factor-II regulates the expression of vascular endothelial growth factor by the human keratinocyte cell line HaCaT. J Invest Dermatol 123:152-158. (Pubitemid 38833476)
26. Kyosseva SV. 2004. Mitogen-activated protein kinase signaling. Int Rev Neurobiol 59:201-220.
27. Kyriakis JM, Avruch J. 2001. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 81:807-869. (Pubitemid 32267078)
28. Lee WS, Chen RJ, Wang YJ, Tseng H, Jeng JH, Lin SY, Liang YC, Chen CH, Lin CH, Lin JK, Ho PY, Chu JS, Ho WL, Chen LC, Ho YS. 2003. In vitro and in vivo studies of the anticancer action of terbinafine in human cancer cell lines: G0/G1 p53-associated cell cycle arrest. Int J Cancer 106:125-137.
29. Liang YC, Huang YT, Tsai SH, Lin-Shiau SY, Chen CF, Lin JK. 1999. Suppression of inducible cyclooxygenase and inducible nitric oxide synthase by apigenin and related flavonoids in mouse macrophages. Carcinogenesis 20:1945-1952. (Pubitemid 29476121)
30. Lin A. 2003. Activation of the JNK signaling pathway: Breaking the brake on apoptosis. Bioessays 25:17-24. (Pubitemid 36093321)
31. Lin SY, Liu JD, Chang HC, Yeh SD, Lin CH, Lee WS. 2002. Magnolol suppresses proliferation of cultured human colon and liver cancer cells by inhibiting DNA synthesis and activating apoptosis. J Cell Biochem 84:532-544.
32. Manning AM, Davis RJ. 2003. Targeting JNK for therapeutic benefit: From junk to gold? Nat Rev Drug Discov 2:554-565.
33. Nakagami H, Morishita R, Yamamoto K, Taniyama Y, Aoki M, Kim S, Matsumoto K, Nakamura T, Higaki J, Ogihara T. 2000. Anti-apoptotic action of hepatocyte growth factor through mitogen-activated protein kinase on human aortic endothelial cells. J Hypertens 18:1411-1420. (Pubitemid 30783555)
34. Nakagami H, Morishita R, Yamamoto K, Taniyama Y, Aoki M, Matsumoto K, Nakamura T, Kaneda Y, Horiuchi M, Ogihara T. 2001. Mitogenic and antiapoptotic actions of hepatocyte growth factor through ERK, STAT3, and AKT in endothelial cells. Hypertension 37:581-586. (Pubitemid 32199031)
35. Oleinik NV, Krupenko NI, Krupenko SA. 2007. Cooperation between JNK1 and JNK2 in activation of p53 apoptotic pathway. Oncogene 26:7222-7230.
36. Pedram A, Razandi M, Levin ER. 1998. Extracellular signal-regulated protein kinase/Jun kinase cross-talk underlies vascular endothelial cell growth factor-induced endothelial cell proliferation. J Biol Chem 273:26722-26728. (Pubitemid 28471688)
37. Petranyi G, Ryder NS, Stutz A. 1984. Allylamine derivatives: New class of synthetic antifungal agents inhibiting fungal squalene epoxidase. Science 224:1239-1241. (Pubitemid 14109460)
38. Potapova O, Gorospe M, Bost F, Dean NM, Gaarde WA, Mercola D, Holbrook NJ. 2000. c-Jun N-terminal kinase is essential for growth of human T98G glioblastoma cells. J Biol Chem 275:24767-24775. (Pubitemid 30626580)
39. Shen YH, Godlewski J, Zhu J, Sathyanarayana P, Leaner V, Birrer MJ, Rana A, Tzivion G. 2003. Cross-talk between JNK/SAPK and ERK/MAPK pathways: Sustained activation of JNK blocks ERK activation by mitogenic factors. J Biol Chem 278:26715-26721. (Pubitemid 36876817)
40. Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA. 2004. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 18:189-218.
41. Tournier C, Hess P, Yang DD, Xu J, Turner TK, Nimnual A, Bar-Sagi D, Jones SN, Flavell RA, Davis RJ. 2000. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science 288:870-874. (Pubitemid 30257738)
42. Uchida C, Gee E, Ispanovic E, Haas TL. 2008. JNK as a positive regulator of angiogenic potential in endothelial cells. Cell Biol Int 32:769-776.
43. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. 1995. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270:1326-1331.